All In Biotech

Drug Trial Radar · NCT04225871

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Dec 23, 2019

Primary completion

Jul 31, 2026

Study completion Jul 31, 2026

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jan 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • zilucoplan (RA101495)Drug

    Daily subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: From Baseline (Day 1) to Safety Follow-Up Visit (up to 36 months)

Locations

70 sites in 10 countries. Site status is shown where the registry gives one.

  • Mg0011 41

    Mobile, Alabama

  • Mg0011 116

    Phoenix, Arizona

  • Mg0011 31

    Irvine, California

  • MG0011 4

    Los Angeles, California

  • Mg0011 220

    Pasadena, California

  • Mg0011 160

    San Francisco, California

  • Mg0011 24

    New Haven, Connecticut

  • Mg0011 27

    Washington D.C., District of Columbia

  • Mg0011 25

    Tampa, Florida

  • Mg0011 135

    Augusta, Georgia

  • Mg0011 188

    Glenview, Illinois

  • Mg0011 156

    Indianapolis, Indiana

  • Mg0011 32

    Kansas City, Kansas

  • Mg0011 33

    Detroit, Michigan

  • Mg0011 49

    East Lansing, Michigan

  • Mg0011 134

    Columbia, Missouri

  • Mg0011 117

    Las Vegas, Nevada

  • Mg0011 30

    Buffalo, New York

  • Mg0011 123

    Great Neck, New York

  • Mg0011 23

    New York, New York

  • Mg0011 47

    New York, New York

  • Mg0011 22

    Chapel Hill, North Carolina

  • Mg0011 122

    Cleveland, Ohio

  • Mg0011 38

    Columbus, Ohio

  • Mg0011 40

    Pittsburgh, Pennsylvania

  • Mg0011 128

    Charleston, South Carolina

  • Mg0011 28

    Cordova, Tennessee

  • Mg0011 131

    Austin, Texas

  • Mg0011 19

    Dallas, Texas

  • Mg0011 39

    Salt Lake City, Utah

  • Mg0011 164

    Charlottesville, Virginia

  • Mg0011 154

    Seattle, Washington

  • Mg0011 45

    Milwaukee, Wisconsin

  • Mg0011 11

    Montreal, Canada

  • Mg0011 204

    Lille, France

  • Mg0011 118

    Nice, France

  • Mg0011 105

    Paris, France

  • Mg0011 137

    Strasbourg, France

  • Mg0011 150

    Göttingen, Germany

  • Mg0011 129

    Tübingen, Germany

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.